文献速递浆细胞疾病造血干细胞移植与细胞治疗

γ分泌酶抑制联合CAR T细胞治疗后多发性骨髓瘤微环境的单细胞分析

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy.
PubMed 文献 · Blood · 2025-01-01

该研究基于crenigacestat(γ分泌酶抑制剂)联合抗BCMA CAR T细胞(FCARH143)的1期临床试验,用单核RNA测序和转座酶可及染色质测序分析肿瘤微环境变化。GSI最显著影响单核细胞,包括非经典单核细胞频率降低及基因表达、染色质可及性和细胞间相互作用改变。部分既往接受抗BCMA治疗患者检出BCMA位点单等位基因缺失,与无进展生存期缩短显著相关(中位PFS 57 vs 861天)。

要点

  • GSI对微环境最显著的影响集中在单核细胞,非经典单核细胞频率降低。
  • GSI暴露后基因表达、染色质可及性和推断的细胞间相互作用均发生显著改变。
  • 部分既往抗BCMA治疗患者存在BCMA位点单等位基因缺失,与PFS缩短相关。

核心结论

  • GSI对肿瘤和免疫细胞群体均有广泛影响,为增强BCMA靶向治疗机制提供线索。

研究设计与样本

  • 基于crenigacestat联合抗BCMA CAR T细胞(FCARH143)的1期临床试验,采用单核RNA测序和转座酶可及染色质测序分析肿瘤微环境。

主要发现

  • GSI最显著的影响涉及单核细胞,并观察到非经典单核细胞频率降低。
  • GSI暴露后基因表达、染色质可及性和推断的细胞间相互作用均发生显著改变。
  • 许多表达改变的基因与γ分泌酶依赖性信号(如Notch)相关,其他通路亦受影响,提示GSI作用广泛。
  • 部分既往接受抗BCMA治疗的患者检出BCMA位点单等位基因缺失,与无进展生存期缩短显著相关(中位PFS 57 vs 861天)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cells and bispecific antibodies targeting B-cell maturation antigen (BCMA) have significantly advanced the treatment of relapsed and refractory multiple myeloma. Resistance to BCMA-targeting therapies, nonetheless, remains a significant challenge. BCMA shedding by γ-secretase is a known resistance mechanism, and preclinical studies suggest that inhibition may improve anti-BCMA therapy. Leveraging a phase 1 clinical trial of the γ-secretase inhibitor (GSI), crenigacestat, with anti-BCMA CAR T cells (FCARH143), we used single-nuclei RNA sequencing and assay for transposase-accessible chromatin sequencing to characterize the effects of GSI on the tumor microenvironment. The most significant impacts of GSI involved effects on monocytes, which are known to promote tumor growth. In addition to observing a reduction in the frequency of nonclassical monocytes, we also detected significant changes in gene expression, chromatin accessibility, and inferred cell-cell interactions after exposure to GSI. Although many genes with altered expression are associated with γ-secretase-dependent signaling, such as Notch, other pathways were affected, indicating GSI has far-reaching effects. Finally, we detected monoallelic deletion of the BCMA locus in some patients with prior exposure to anti-BCMA therapy, which significantly correlated with reduced progression-free survival (PFS; median PFS, 57 vs 861 days). GSIs are being explored in combination with the full spectrum of BCMA-targeting agents, and our results reveal widespread effects of GSI on both tumor and immune cell populations, providing insight into mechanisms for enhancing BCMA-directed therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Coffey DG, Ataca Atilla P, Atilla E, et al. Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy. Blood. 2025. PMID: 39374522. doi:10.1182/blood.2024025231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。